Song Ou Zhang

Dr. Song Ou Zhang

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2024 in Frontiers in Bioengineering and Biotechnology
Verified
Journal Article
Open access
PDF file
WHWei He
Wei He
CJChao Jiang
Chao Jiang
PZPing Zhou
Ping Zhou
XHXujun Hu
Xujun Hu
XGXiaoPeng Gu
XiaoPeng Gu
SZSong Ou Zhang
Song Ou Zhang
This review offered a comprehensive analysis of tendon and ligament injuries, emphasizing the crucial role of tendon-derived stem cells (TDSCs) in tissue engineering as a potential solution for these challenging medical conditions. Tendon and ligament injuries, prevalent among athletes, the elderly, and laborers, often result in long-term disability and reduced quality of life due to the poor intrinsic healing capacity of these avascular structures. The formation of biomechanically inferior scar tissue and a high rate of reinjury underscore the need for innovative approaches to enhance and guide the regenerative process. This review delved into the complexities of tendon and ligament structure and function, types of injuries and their impacts, and the limitations of the natural repair process. It particularly focused on the role of TDSCs within the context of tissue engineering. TDSCs, with their ability to differentiate into tenocytes, are explored in various applications, including biocompatible scaffolds for cell tracking, co-culture systems to optimize tendon-bone healing, and graft healing techniques. The review also addressed the challenges of immunoreactivity post-transplantation, the importance of pre-treating TDSCs, and the potential of hydrogels and decellularized matrices in supporting tendon regeneration. It concluded by highlighting the essential roles of mechanical and molecular stimuli in TDSC differentiation and the current challenges in the field, paving the way for future research directions.

6 September 2023 in BMC Musculoskeletal Disorders
Verified
Journal Article
Open access
PDF file
LQLianjun Qu
Lianjun Qu
YWYongli Wang
Yongli Wang
FWFei Wang
Fei Wang
SZSong Ou Zhang
Song Ou Zhang
In recent years, with improved living standards, adolescent obesity has been increasingly studied. The incidence of lumbar disc herniation (LDH) in obese adolescents is increasing yearly. No clinical studies have reported the use of percutaneous endoscopic lumbar discectomy (PELD) in obese adolescent lumbar disc herniation (ALDH) patients. This study evaluated the preliminary surgical outcomes of PELD in obese ALDH patients. Fifty-one ALDH patients underwent single-level PELD surgery between January 2014 and January 2020. Patients were divided into an obese group and a normal group. Patient characteristics and surgical variables were compared between the two groups. The VAS, ODI, and SF-36 scales were used preoperatively and postoperatively to evaluate the clinical efficacy. In this study, 19 patients were included in the obese group, and 28 were included in the normal group. There was no significant difference in age, sex, duration of low back pain, duration of leg pain, or operative level between the obese and normal groups preoperatively. The obese group had a longer operative time (OT) (101.9 ± 9.0 min vs. 84.3 ± 11.0 min, P < 0.001), more fluoroscopy exposures (41.0 ± 5.8 vs. 31.6 ± 7.0, P < 0.001) and a longer time to ambulation (29.9 ± 4.0 vs. 25.0 ± 2.9, p < 0.001) than the normal group. The groups did not significantly differ in complications. The VAS score for back and leg pain and the ODI and SF-36 score for functional status improved significantly postoperatively. The PELD procedure is a safe and feasible method for treating LDH in obese adolescents. Obese ALDH patients require a longer OT, more fluoroscopy exposures and a longer time to get out of bed than normal ALDH patients. However, PELD yields similar clinical outcomes in obese and normal ALDH patients.

16 May 2025 in Journal of Orthopaedic Translation
Verified
Journal Article
Open access
XXXiaochun Xiong
Xiaochun Xiong
CZChao Zhou
Chao Zhou
YYYijun Yu
Yijun Yu
QXQiong Xie
Qiong Xie
LXLinying Xia
Linying Xia
WLWenqing Liang
Wenqing Liang
Spinal cord injury (SCI) remains an unresolved and complex medical challenge. In SCI, mitochondrial dysfunction leads to calcium overload and an increase in reactive oxygen species (ROS). Intercellular mitochondrial transfer has the potential to rescue surviving neurons, while exogenous mitochondrial transplantation can be performed through direct injection or cell-assisted methods. This review explored the current state of research on mitochondrial transplantation and transfer as potential treatments for SCI. It also analyzed the therapeutic implications, influencing factors, and advanced delivery methods for both endogenous mitochondrial transfer and exogenous mitochondrial transplantation. Furthermore, future research directions, including optimizing mitochondrial delivery methods, determining optimal dosages for different delivery approaches, were discussed based on larger animal models and clinical trials. The goal of this review was to introduce novel concepts and prospects for SCI therapy and to contribute to the advancement of medical research in this field. At present, SCI lacks effective therapies, with mitochondrial dysfunction playing a central role in neuronal damage. Mitochondrial transplantation holds promise for restoring bioenergetic function. However, key challenges remain, including optimizing delivery methods, determining appropriate dosages, scalability, donor mitochondrial sourcing, regulatory hurdles and ensuring successful integration. Addressing these issues requires non-invasive platforms, validation in large-animal models, and clinical trials. This approach may bridge mitochondrial biology with translational engineering, thereby advancing the development of regenerative therapies for SCI.

1 August 2025 in Medicine
Verified
Journal Article
Open access
JSJinxiang Shang
Jinxiang Shang
CJcong jin
cong jin
FWFei Wang
Fei Wang
ZZZhenyu Zhang
Zhenyu Zhang
LXLu Xie
Lu Xie
JLJianlei Li
Jianlei Li
Background: Diabetic foot, a common complication of diabetes, impairs wound healing, leading to ulcers and an increased risk of amputation. Growth factors play a critical role in the management of diabetic foot, influencing wound repair and tissue regeneration. This study employs bibliometric analysis to assess research on growth factors in diabetic foot and predict future research trends. Methods: Scholarly articles published between January 1, 2008, and March 31, 2024, were retrieved from the Web of Science Core Collection database. Analytical and visualization tools such as VOSviewer, CiteSpace, R software, PRISM, and Scimago were utilized for the study. Results: Over the past 17 years, the number of publications has steadily increased. Aristidis Veves is the most prominent author, with Harvard University being the leading institution. The most cited papers are “Recent Advances in the Development of Wound Dressings for Diabetic Foot Ulcer Treatment” and “Wound Healing and Its Impairment in the Diabetic Foot.” Key research areas include cellular mechanisms, economic burden, and treatment targets. Current research hotspots focus on oxidative stress and diabetic wound healing, with future trends leaning toward personalized medicine and advanced technologies. Conclusion: This bibliometric analysis highlights current trends in growth factor research for diabetic foot, emphasizing oxidative stress and personalized medicine as emerging areas. These findings provide valuable insights for future research and potential improvements in treatment strategies, with the goal of enhancing patient outcomes and reducing the burden of diabetic foot complications.

1 January 2026 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
HYHaizhou Ying
Haizhou Ying
CZChao Zhou
Chao Zhou
XLXiankun Liu
Xiankun Liu
SQShu Qin
Shu Qin
LCLin Chen
Lin Chen
WLWenqing Liang
Wenqing Liang
The clinical management of bone defects presents a significant challenge in regenerative medicine due to the limited self-repair capacity of bone tissue and inadequate vascularization. Nitric oxide, a gaseous signaling molecule, has garnered attention as a potent modulator of bone remodeling, exhibiting pro-osteogenic, pro-angiogenic, and anti-inflammatory properties. However, its therapeutic application is limited by its short half-life, high reactivity, and dose-dependent biphasic effects. Advanced polymer-based nanoformulations have been developed to address these challenges and enable controlled and localized NO delivery to bone tissue. This review explores role of NO in bone repair mechanisms and the limitations of conventional delivery systems. Significant focus is given to innovative polymeric platforms, such as dendrimers, micelles, nanogels, and hybrid composites, which offer precise control over release kinetics, high encapsulation efficiency, and targeted delivery. Additionally, integrating NO delivery within nanoengineered scaffolds and coatings for orthopedic implants is explored as a promising strategy to enhance osteointegration and reduce the risk of post-surgical infections. Preclinical studies demonstrate promising osteogenic effects yet face significant challenges including cytotoxicity at elevated NO concentrations along with non-standardized evaluation protocols and scalability limitations. Future perspectives point to the potential of stimuli-responsive systems, co-delivery approaches, and personalized strategies utilizing additive manufacturing technologies. This review consolidates the latest advancements in the field, underscoring the significant potential of polymer-based NO nanoformulations to revolutionize bone tissue engineering.

6 May 2026 in Journal of Orthopaedic Translation
Verified
Journal Article
Open access
SJSongTao Jin
SongTao Jin
YMYueGang Ma
YueGang Ma
SZSong Ou Zhang
Song Ou Zhang
Spinal cord injury (SCI) represents a critical neurological disorder characterized by intricate pathophysiological processes. The hostile local environment induced by secondary damage markedly hinders intrinsic neural repair, and currently available therapies exhibit limited clinical effectiveness. Recently, mesenchymal stem cells (MSCs) have attracted considerable attention due to their paracrine-mediated therapeutic properties, including immunoregulatory effects, neurotrophic factor secretion, and promotion of angiogenesis. Nevertheless, conventional transplantation of MSCs encounters substantial obstacles, such as poor cellular viability post-injection, inadequate homing capabilities, and diminished therapeutic outcomes in the unfavorable post-injury microenvironment. Therefore, it is essential to “functionalize” MSCs to enhance their therapeutic potential. This article systematically reviews three major MSC functionalization strategies: biomaterial-based delivery platforms, genetic engineering approaches, and drug or physical synergistic therapies. Preclinical evidence indicates that these strategies can synergistically improve motor function recovery, promote axonal regeneration and myelination, and suppress inflammatory responses. Overall, functionalized MSC therapy shows greater therapeutic promise than traditional cell transplantation. Future studies should prioritize challenges related to safety, standardization, and large-scale production to support clinical translation, and should further explore multimodal functional integration and intelligent, responsive stem cell systems to achieve breakthroughs in SCI treatment. This article presents a multidimensional therapeutic framework that integrates biomaterial-based delivery platforms, genetic engineering modifications, and non-invasive preconditioning methods to synergistically enhance the survival and functionality of transplanted cells within the hostile injury microenvironment. Preclinical evidence demonstrates these approaches effectively promote motor recovery, axonal regeneration, and inflammatory modulation, while preliminary clinical studies confirm their long-term safety and efficacy in improving neurological function. However, clinical translation faces challenges including the long-term safety of gene editing, standardization of treatment protocols, and the efficacy gap between animal models and human applications.